interim analysis

3 Biotech Stocks Getting Some Love -Genocea Biosciences Inc (NASDAQ:GNCA …
www.wsobserver.com

The company, on October 7, 2015, declaredpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

6
Like
Save
Premarket Biotech Digest: Evoke Pharma Rallies, Avelumab Fast Tracked, Vertex …
seekingalpha.com

… Phase II Trial of GEN-003 – Genocea Biosciences (NASDAQ:GNCA) announced positive results from a planned interim analysis of data collected six months after dosing from its Phase II dose optimization trial of GEN-003 for the treatment of genital herpes.

2
Like
Save
Genocea Bio's GEN-003 achieves primary endpoint in mid-stage genital herpes …
seekingalpha.com

An interim analysis of six-month data from a Phase 2 clinical trial evaluating Genocea Biosciences' (NASDAQ:GNCA) lead product candidate GEN-003 for the treatment of genital herpes showed a 58% reduction from baseline in the viral shedding rate …

7
Like
Save
Checklist Early morning Stocks: SBA Communications Corporation (NASDAQ:SBAC …
www.wsnews4investors.com

Genocea Biosciences, Inc. (GNCA reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

3
Like
Save
Pre-market most advance: Genocea Biosciences (NASDAQ:GNCA), Breitburn Energy …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

3
Like
Save
Pre-Open Stock Movers 10/07: (GNCA) (SUNE) (GBX) Higher; (AXPW) (ADXS) (YUM …
www.streetinsider.com

… Inc. (NASDAQ: GNCA) 21.9% HIGHER; announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its …

8
Like
Save
Health Care Sector Update for 10/07/2015: SNY, ADPT, GNCA
www.nasdaq.com

a biopharmaceutical company, said interim analysis of Phase 2 data on its GEN-003 genital herpes vaccine demonstrated a statistically significant 58% reduction in the viral shedding rate, the primary endpoint of the study. Shares in the company were …

8
Like
Save
Admedus' CardioCel® shows promise to treat congenital heart disease
www.proactiveinvestors.co.uk

The 57%-owned Admedus Vaccines has created a DNA vaccine for HSV-2 infection with both prophylactic and therapeutic potential in genital herpes. This has worked well on an interim analysis of Phase I, with a therapeutic T cell response in HSV-2 naïve …

3
Like
Save
Admedus' CardioCel® shows promise to treat congenital heart disease
www.proactiveinvestors.com

The 57%-owned Admedus Vaccines has created a DNA vaccine for HSV-2 infection with both prophylactic and therapeutic potential in genital herpes. This has worked well on an interim analysis of Phase I, with a therapeutic T cell response in HSV-2 naïve …

9
Like
Save
Admedus' CardioCel® shows promise to treat congenital heart disease
www.proactiveinvestors.com.au

The 57%-owned Admedus Vaccines has created a DNA vaccine for HSV-2 infection with both prophylactic and therapeutic potential in genital herpes. This has worked well on an interim analysis of Phase I, with a therapeutic T cell response in HSV-2 naïve …

3
Like
Save